2019 policy bargaining drugs ranking

At the end of the year, the major media in various industries started a new round of inventory Throughout the pharmaceutical industry, this year's inventory of "bottom materials" is excessive From policies to drug prices, from layoffs to job hopping, from compensation to new drugs More is the "topx" of inventory, less is the "hair" of small knitting Among these many "bottom materials", the most distressing thing for pharmaceutical companies is the policy pricing A pill is not worth a mouthful of mineral water?! And this series of policy bargain, and life forced out a variety of drug prices!!! In 2019, under the interweaving of a series of policies, no matter drugs or medical devices, no matter production or circulation terminals, there will be many changes But looking back, we will find that among these intensive policies, there are three policies that are undoubtedly the most "destructive" to pharmaceutical companies, and they step by step push generic drugs into the "meager profit era" "" There is no doubt that 2019 is an eventful year for medical people, and the first major event to start this eventful year is the first round of "4 + 7" volume procurement It can be said that the "4 + 7" volume purchase has pushed the upgrade button for the national ten-year medical reform On December 7, 2018, the first batch of "4 + 7" City drug centralized procurement announced the proposed selection results, which clarified the drug procurement varieties and procurement volume of 11 pilot cities In March this year, the detailed rules for the implementation of volume procurement in 11 pilot cities were all implemented From the perspective of procurement content, the first batch of "4 + 7" volume procurement of a total of 25 varieties, mostly for patients with chronic diseases, including 22 generic drugs through consistency evaluation, accounting for 88%, 3 original research drugs, accounting for 12% The average price of the proposed medium-sized selection will be reduced by 52% with a maximum decrease of 96% From the implementation results, on September 26, the head of the pilot office of the state health insurance bureau said that the implementation of the pilot centralized mining work was generally stable, the implementation progress exceeded expectations, the public opinion was good, and the burden of patients' medication costs was significantly reduced As of the end of August, the purchase volume of 25 selected drugs in "4 + 7" cities was 1.7 billion, and the implementation of the agreed total purchase progress was better than expected Many senior medical professionals said that compared with any previous medical reform policy, the most direct and perceptible effect of "4 + 7" volume purchase is that the price of drugs purchased with volume is "surprisingly low" compared with the previous one With the momentum of cutting the mess quickly, it can effectively solve the problems of high drug price and medical insurance cost control "" With the promotion of "4 + 7" pilot work, the price "depression" of relevant drugs in "4 + 7" pilot cities has been formed People in non pilot areas are increasingly eager to expand the scope of the pilot On the basis of the pilot evaluation and the summary of relevant experience, the state decided to launch the pilot in an all-round way On September 1, 2019, Shanghai Sunshine pharmaceutical purchase network released the document of centralized drug purchase in the alliance region, and the pilot cities for centralized drug purchase and use organized by the state officially expanded The alliance area includes 25 provinces (regions and cities) including Shanxi Province, Inner Mongolia Autonomous Region and Liaoning Province, with the exception of "4 + 7" cities in the alliance area The first batch of "4 + 7" 25 varieties purchased with quantity will be continued Compared with the lowest purchase price in 2018 in the alliance region, the proposed mid-term selection price dropped by 59% on average and 25% on average compared with the "4 + 7" pilot mid-term selection price level For the impact of the expansion of volume procurement, the head of the pilot said: after the expansion of the pilot, 25 pharmaceutical volume procurement will cover all regions of the country, with higher requirements for product quality, capacity supply and cost control of enterprises, and enterprises will face greater competitive pressure, which will be conducive to promoting the optimization and restructuring of the industry, gradually changing the situation of small industry scale and low quality, and promoting industry regulations Modular, intensive and modern development "" On November 28, the State Medical Security Bureau and the Ministry of human resources and social security released the complete 2019 national directory of drugs for basic medical insurance, work injury insurance and maternity insurance, which included 2709 drugs in total According to the negotiation results, the 150 drugs included in the negotiation were totally 97, all of which were included in category B of the catalogue Among them, 70 of the 119 new varieties negotiated successfully, with an average decrease of 60.7% The decrease rate of three kinds of hepatitis B drugs was more than 85%, and that of tumor diabetes was more than 65% In addition, 27 of the 31 renewal drugs confirmed in 2017 were successfully negotiated, with a decrease of 26.4% Most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc According to experts, in this medical insurance catalog, several world-famous "noble drugs" have been marked with "civilian price", and the imported drugs have basically given the lowest price in the world It is conservatively estimated that through negotiation of price reduction and medical insurance reimbursement, the individual burden of patients will be reduced to less than 20% of the original level, and the individual drugs will be reduced to less than 5% Under the bargaining of three policies, the price of drugs has been reduced in the form of "jumping off the building" From the three highs to cancer drugs, the drop in the price of drugs has shocked the patients' chin, and they have expressed that they dare not use them, for fear of fake drugs Finally, I was willing to use it, but I didn't think the price of the medicine was worth the ticket to the hospital So how tough is drug price reduction? From the following list of drug price reductions, we can clearly understand the "hero" drugs and their companies that have been at the forefront of price reductions in this year From the above form, we can get the following information: 1 In the top 50 price reduction list, Huahai pharmaceutical and Qilu pharmaceutical respectively "contributed" 5 varieties, which is an outstanding representative of "price for quantity" For enterprises, "price for quantity" is to seek a balance between profits and expanding the coverage of drugs Especially for innovative drugs, expanding market coverage is sometimes more attractive than profits.